Laparoscopic Promontofixation for Pelvic Organ Prolapse: a 10-year Single Center Experience in a Series of 501 Patients
Overview
Authors
Affiliations
Objectives: To assess the long-term outcomes of laparoscopic promontofixation (LP) for the treatment of pelvic organ prolapse (POP).
Methods: A total of 501 consecutive patients with POP were included in this prospective study. The patients' mean age was 63.23 (36-90) years, their mean body mass index was 25.14 (15-36) and their mean number of deliveries was 3.3 (0-14). A POP grade ≥3 was diagnosed in 70.4% of the patients and 38.9% of them had a history of abdominal surgery. The patients underwent a Bonney test and urodynamic study. In cases of stress urinary incontinence (SUI), the patients underwent the simultaneous insertion of a tension-free vaginal tape. A prolapse quality of life questionnaire was sent to all patients.
Results: The mean operative time was 97.4 min (50-210) and there were 1.7% cases of intra-operative complications. The mean hospitalization time was 3.7 days (1-13 days). During the mean follow-up of 20.7 months (3-120), 91 (17.8%) complications were recorded, including constipation (5.5%), SUI (3.5%), vaginal erosion (2.4%), and urge incontinence (2%). Recurrences were recorded in 11.5% of the patients within an average time of 37.2 months. Risk factors for recurrence were the use of the polypropylene mesh compared with the polyester mesh (P<0.0001), an intra-operative hysterectomy (P=0.02), and bleeding (P=0.049). There was a statistical significant (P<0.001) improvement in most of the symptoms in the prolapse quality of life questionnaire.
Conclusions: LP is safe with effective long-term results, with low recurrence and morbidity rates, and a good quality of life.
Post-operative outcomes associated with anterior mesh location after laparoscopic sacrocolpopexy.
Habib N, Giorgi M, Tahtouh T, Hamdi A, Centini G, Cannoni A Arch Gynecol Obstet. 2024; 310(5):2717-2724.
PMID: 39322854 DOI: 10.1007/s00404-024-07719-4.
Comparison of first versus second line sacrocolpopexies in terms of morbidity and mid-term efficacy.
Lallemant M, Grob A, Puyraveau M, Perik M, Alhafidh A, Cosson M Sci Rep. 2022; 12(1):16283.
PMID: 36175515 PMC: 9522651. DOI: 10.1038/s41598-022-20127-5.
Kotani Y, Murakamsi K, Kai S, Yahata T, Kanto A, Matsumura N Gynecol Minim Invasive Ther. 2021; 10(4):221-225.
PMID: 34909379 PMC: 8613493. DOI: 10.4103/GMIT.GMIT_127_20.
Harvey M, Chih H, Geoffrion R, Amir B, Bhide A, Miotla P Int Urogynecol J. 2021; 32(10):2575-2594.
PMID: 34338825 DOI: 10.1007/s00192-021-04941-5.
Mourad S, El Shawaf H, Farouk A, Maged H, Noweir A, Deval B Arab J Urol. 2020; 17(1):30-39.
PMID: 33110660 PMC: 7567316. DOI: 10.1080/2090598X.2019.1589781.